Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuji Shibata

Showing results (31-40 of 57) with videos related to

Pageof 6
Sort By:
Scientific Reports|December 14, 2016
Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysisKenjiro Nagai, Nobuyuki Horita, Masaki Yamamoto, et al.
Tuberculosis (Edinburgh, Scotland)|July 25, 2016
Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasmaRyota Ushio, Masaki Yamamoto, Kentaro Nakashima, et al.
Scientific Reports|October 22, 2015
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 PatientsNobuyuki Horita, Masaki Yamamoto, Takashi Sato, et al.
Scientific Reports|January 12, 2016
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patientsNobuyuki Horita, Masaki Yamamoto, Takashi Sato, et al.
International Journal of Cancer|October 12, 2018
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitorNorikazu Matsuo, Koichi Azuma, Satoshi Hattori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2026
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistanceHibiki Udagawa, Yuji Shibata, Monique B Nilsson, et al.
Cancer Treatment and Research Communications|January 20, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutationHiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, et al.
JTO Clinical and Research Reports|April 6, 2026
Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia RegistryShingo Matsumoto, Takashi Seto, Christer Svedman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2023
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)Tetsuya Sakai, Shingo Matsumoto, Yasuto Ueda, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2023
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutationShingo Kitagawa, Yoshitaka Zenke, Tetsuro Taki, et al.
Pageof 6

Showing results (31-40 of 57) with videos related to

Sort By:
Pageof 6
Scientific Reports|December 14, 2016
Diagnostic test accuracy of loop-mediated isothermal amplification assay for Mycobacterium tuberculosis: systematic review and meta-analysisKenjiro Nagai, Nobuyuki Horita, Masaki Yamamoto, et al.
Tuberculosis (Edinburgh, Scotland)|July 25, 2016
Digital PCR assay detection of circulating Mycobacterium tuberculosis DNA in pulmonary tuberculosis patient plasmaRyota Ushio, Masaki Yamamoto, Kentaro Nakashima, et al.
Scientific Reports|October 22, 2015
Topotecan for Relapsed Small-cell Lung Cancer: Systematic Review and Meta-Analysis of 1347 PatientsNobuyuki Horita, Masaki Yamamoto, Takashi Sato, et al.
Scientific Reports|January 12, 2016
Amrubicin for relapsed small-cell lung cancer: a systematic review and meta-analysis of 803 patientsNobuyuki Horita, Masaki Yamamoto, Takashi Sato, et al.
International Journal of Cancer|October 12, 2018
Association between soluble immune mediators and tumor responses in patients with nonsmall cell lung cancer treated with anti-PD-1 inhibitorNorikazu Matsuo, Koichi Azuma, Satoshi Hattori, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 23, 2026
Adaptive feedback signaling via the FAK/SRC pathway promotes KRAS G12C inhibitor resistanceHibiki Udagawa, Yuji Shibata, Monique B Nilsson, et al.
Cancer Treatment and Research Communications|January 20, 2026
Phase 1/2 trial of brigatinib plus panitumumab in patients with osimertinib-resistant EGFR-mutated non-small cell lung cancer harboring EGFR C797S mutationHiroki Izumi, Tomohiro Sakamoto, Ken Uchibori, et al.
JTO Clinical and Research Reports|April 6, 2026
Clinical Concordance of Pan Lung Cancer PCR Panel Covering 167 Actionable Variants Across 11 Genes and Other Validated Assays in the LC-SCRUM-Asia RegistryShingo Matsumoto, Takashi Seto, Christer Svedman, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 5, 2023
Clinicogenomic Features and Targetable Mutations in NSCLCs Harboring BRAF Non-V600E Mutations: A Multi-Institutional Genomic Screening Study (LC-SCRUM-Asia)Tetsuya Sakai, Shingo Matsumoto, Yasuto Ueda, et al.
Lung Cancer (Amsterdam, Netherlands)|December 31, 2023
Prognostic value of predominant subtype in pathological stage II-III lung adenocarcinoma with epidermal growth factor receptor mutationShingo Kitagawa, Yoshitaka Zenke, Tetsuro Taki, et al.
Pageof 6